Helmy Karim Y, Patel Shyam A, Nahas George R, Rameshwar Pranela
Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Ther Deliv. 2013 Oct;4(10):1307-20. doi: 10.4155/tde.13.88.
Cancer remains a devastating disease as existing therapies are too often ineffective and toxicities remain unacceptably high. Immunotherapies for cancer offer the promise of the specificity and memory of the immune system against malignant cells to achieve durable cure with minimal toxicity. Beginning with the success of bone marrow transplantation for blood-borne cancers, and the more recent development of monoclonal antibody therapeutics for a variety of tumors, immunotherapies are already among the most successful class of treatments for cancer. Greater understanding of immunoregulatory mechanisms and improved techniques for immune cell manipulation and engineering have led to new immunomodulatory approaches and cell-based therapies for cancer that have generated great excitement within the biomedical community. As these technologies continue to improve, and as new approaches for harnessing the power and specificity of the immune system are developed, immunotherapies will play an increasingly important role in the treatment of cancer. Here, we review the history of immunotherapies for cancer and discuss existing and emerging immunotherapy technologies that hope to translate the promise of immunotherapy into clinical reality.
癌症仍然是一种毁灭性的疾病,因为现有的治疗方法往往无效,且毒性高得令人难以接受。癌症免疫疗法有望利用免疫系统针对恶性细胞的特异性和记忆功能,以最小的毒性实现持久治愈。从血液系统癌症的骨髓移植成功,到最近针对各种肿瘤的单克隆抗体疗法的发展,免疫疗法已经成为最成功的癌症治疗方法之一。对免疫调节机制的更深入了解以及免疫细胞操作和工程技术的改进,催生了新的免疫调节方法和基于细胞的癌症疗法,这些疗法在生物医学界引起了极大的轰动。随着这些技术不断改进,以及利用免疫系统的力量和特异性的新方法不断涌现,免疫疗法在癌症治疗中将发挥越来越重要的作用。在此,我们回顾癌症免疫疗法的历史,并讨论现有的和新兴的免疫治疗技术,这些技术希望将免疫疗法的前景转化为临床现实。
Ther Deliv. 2013-10
Immunol Lett. 2014-12
Cytokines Mol Ther. 1996-3
Adv Drug Deliv Rev. 2017-5-15
Arch Immunol Ther Exp (Warsz). 2002
Dtsch Med Wochenschr. 2008-10
Pathol Res Pract. 2021-2
Clin Sci (Lond). 2019-1-18
Crit Rev Clin Lab Sci. 2009
In Vitro Model. 2023-11-13
Heliyon. 2024-9-27
Front Immunol. 2024
Biomark Res. 2024-5-30
Discov Oncol. 2024-5-16
Eur J Clin Pharmacol. 2024-6